Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AUROVELA FE 1.5/30 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone acetate and ethinyl estradiol. Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides feedback inhibition of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing follicular development and ovulation. Additionally, it causes changes in cervical mucus (increased viscosity) and endometrium (reduced receptivity).
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy (FDA-approved),Treatment of moderate acne vulgaris in females at least 15 years of age who have no known contraindications to oral contraceptive therapy and have achieved menarche (off-label but common use),Management of menstrual disorders (off-label): dysmenorrhea, menorrhagia, irregular bleeding,Hormonal contraception in patients with iron deficiency anemia (due to iron supplementation in formulation)
Prevention of pregnancy (FDA-approved)
One tablet orally once daily at the same time each day for 28 consecutive days.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 5-14 hours (terminal); Ethinyl estradiol: 10-20 hours (terminal). Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Norethindrone acetate is metabolized primarily in the liver via reduction and conjugation (sulfation and glucuronidation). It is a prodrug, rapidly hydrolyzed to norethindrone. Ethinyl estradiol is metabolized via CYP3A4 in the liver, undergoing hydroxylation, methylation, and conjugation (glucuronidation and sulfation). Both undergo enterohepatic recirculation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~50-60% as metabolites, <10% unchanged; Fecal: ~40-50% via bile; Ethinyl estradiol undergoes enterohepatic recirculation.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: ~97% (albumin and SHBG); Ethinyl estradiol: ~97-98% (albumin, not SHBG).
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 2-5 L/kg (extensive tissue distribution); Ethinyl estradiol: 2-4 L/kg (distributes into breast milk and body fat).
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Norethindrone ~64% (first-pass effect); Ethinyl estradiol ~40-45% (extensive first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min/1.73 m²); use is not recommended.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in severe hepatic disease (Child-Pugh class C). Use with caution and monitor liver function in mild to moderate impairment (Child-Pugh A/B); consider alternative methods if liver function deteriorates.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific studies in elderly; consider age-related risks of thromboembolism and cardiovascular disease.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS. Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years of age, and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders: risk of venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction; increased in smokers, obese, or those with thrombogenic mutations,Hepatic neoplasia: rare cases of benign and malignant liver tumors reported,Ocular effects: retinal thrombosis, papilledema, optic neuritis,Cardiovascular: hypertension, lipid effects, increased risk in women with hypertension or hyperlipidemia,Carbohydrate metabolism: impaired glucose tolerance, increased insulin resistance,Headache/migraine: discontinue if new or worsening migraine or severe headache,Bleeding irregularities: breakthrough bleeding, spotting, amenorrhea,Gallbladder disease: increased risk,Depression: can exacerbate,Hereditary angioedema: may trigger or worsen,Chloasma: may cause melasma, exacerbated by sun exposure,Iron supplementation: caution in hemochromatosis or iron overload disorders,Dental/gingival: gingivitis,Laboratory tests: may affect thyroid, sex hormone-binding globulin, coagulation factors
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Current or past history of thrombophlebitis or venous thromboembolism,Cerebrovascular or coronary artery disease (current or history),Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,Known or suspected estrogen-dependent neoplasia (e.g., breast cancer, endometrial cancer),Active liver disease, impaired liver function, or benign/malignant liver tumors (current or history),Hypersensitivity to any component of the product,Women over 35 years of age who smoke cigarettes,Uncontrolled hypertension (blood pressure >160/100 mm Hg),Migraine with aura at any age,Diabetes mellitus with vascular involvement,Major surgery with prolonged immobilization,Current or history of breast cancer (confirmed or suspected)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit and grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No other significant food interactions. Take with food or milk to reduce gastrointestinal upset if needed.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Contraindicated in pregnancy. Use during first trimester associated with oral clefts and cardiac defects; second and third trimester exposure linked to feminization of male fetuses and other anomalies due to progestin effects. Increased risk of ectopic pregnancy. On-label indications exclude pregnancy use.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk; M/P ratio unknown. May reduce milk production and alter composition. Use only if benefits outweigh risks, with monitoring for infant jaundice and weight gain. Consider alternative contraception during breastfeeding.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable; drug is contraindicated in pregnancy. No dose adjustments recommended as therapy should be discontinued immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
AUROVELA FE 1.5/30 is a combined oral contraceptive containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg. It contains ferrous fumarate as an iron supplement in the placebo pills. Patients with a history of venous thromboembolism, thrombogenic mutations, or estrogen-sensitive malignancies should not use this medication. Baseline blood pressure, lipid profile, and liver function tests are recommended. Counsel patients to take at the same time daily to maintain efficacy. Consider drug interactions with antibiotics, anticonvulsants, and St. John's Wort which may reduce contraceptive effectiveness.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time each day, with or without food.,Swallow tablets whole; do not crush or chew.,Missed dose management: if missed by less than 12 hours, take it as soon as remembered; if more than 12 hours, skip the missed dose and continue with next tablet; use back-up contraception if multiple doses missed.,Common side effects include nausea, breast tenderness, weight changes, and breakthrough bleeding; these may improve after 2-3 cycles.,Seek immediate medical attention if you experience leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Does not protect against sexually transmitted infections (STIs); use condoms for STI prevention.,Inform your healthcare provider of all medications, including over-the-counter drugs and herbal supplements.,Continue taking the iron-containing placebo tablets during the placebo week; do not skip.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AUROVELA FE 1.5/30 vs AFIRMELLE, answered by our medical review team.
AUROVELA FE 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone acetate and ethinyl estradiol. Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides feedback inhibition of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing follicular development and ovulation. Additionally, it causes changes in cervical mucus (increased viscosity) and endometrium (reduced receptivity).. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AUROVELA FE 1.5/30 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AUROVELA FE 1.5/30 is: One tablet orally once daily at the same time each day for 28 consecutive days.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AUROVELA FE 1.5/30 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AUROVELA FE 1.5/30 is classified as Category C. Contraindicated in pregnancy. Use during first trimester associated with oral clefts and cardiac defects; second and third trimester exposure linked to feminization of male fetuses. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.